U.S. patent application number 10/512512 was filed with the patent office on 2006-01-26 for peptide composition.
Invention is credited to John Arthur Smith.
Application Number | 20060019884 10/512512 |
Document ID | / |
Family ID | 9935427 |
Filed Date | 2006-01-26 |
United States Patent
Application |
20060019884 |
Kind Code |
A1 |
Smith; John Arthur |
January 26, 2006 |
Peptide composition
Abstract
Provided is use of a peptide, or a derivative of a peptide, in
the manufacture of a medicament effective in stimulating
fibroblasts to produce fibrillin, wherein the peptide comprises an
amino acid sequence present in an .alpha.-S2 casein precursor, said
sequence comprising 3 or more amino acids, and not comprising at
its N-terminal amino acid of the full .alpha.-S2 casein precursor.
Further provided is use of a peptide, or a derivative of a peptide,
in the manufacture of a medicament effective in stimulating
fibroblasts to produce fibrillin, wherein the peptide has an
.alpha.-S2 casein fragment activity.
Inventors: |
Smith; John Arthur;
(Liverpool, GB) |
Correspondence
Address: |
DORSEY & WHITNEY LLP;INTELLECTUAL PROPERTY DEPARTMENT
250 PARK AVENUE
NEW YORK
NY
10177
US
|
Family ID: |
9935427 |
Appl. No.: |
10/512512 |
Filed: |
April 2, 2003 |
PCT Filed: |
April 2, 2003 |
PCT NO: |
PCT/GB03/01439 |
371 Date: |
July 7, 2005 |
Current U.S.
Class: |
514/17.2 ;
514/18.8; 514/5.7 |
Current CPC
Class: |
A61P 17/16 20180101;
A61K 38/1709 20130101; A61K 8/64 20130101; A61P 1/02 20180101; A61Q
11/00 20130101; A61P 17/00 20180101; A61Q 19/08 20130101; A61K
2800/70 20130101; A61P 43/00 20180101 |
Class at
Publication: |
514/012 ;
514/013; 514/014; 514/015 |
International
Class: |
A61K 38/17 20060101
A61K038/17; A61K 38/10 20060101 A61K038/10 |
Foreign Application Data
Date |
Code |
Application Number |
Apr 24, 2002 |
GB |
0209384.7 |
Claims
1. Use of a peptide, or a derivative of a peptide, in the
manufacture of a medicament effective in stimulating fibroblasts to
produce fibrillin, wherein the peptide comprises an amino acid
sequence present in an .alpha.-S2 casein precursor, said sequence
comprising 3 or more amino acids, and not comprising at its
n-terminus the N-terminal amino acid of the full .alpha.-S2 casein
precursor.
2. Use of a peptide, or a derivative of a peptide, in the
manufacture of a medicament effective in stimulating fibroblasts to
produce fibrillin, wherein the peptide has an .alpha.-S2 casein
fragment activity.
3. Use according to claim 1 or claim 2, wherein the medicament is
effective in alleviating or preventing periodontal disease.
4. Use according to claim 1 or claim 2, wherein the medicament is
effective in alleviating or preventing an effect of aging in
skin.
5. Use according to any preceding claim, wherein the peptide
comprises 9 or more amino acids.
6. Use according to any preceding claim, wherein the peptide
comprises from 9-31 amino acids.
7. Use according to any preceding claim, wherein the peptide
comprises the C-terminus of the full .alpha.-S2 casein
precursor.
8. Use according to any preceding claim, wherein the peptide is
derived from bovine, goat, sheep, rabbit or pig .alpha.-S2 casein
or is a synthesized equivalent or homologue thereof.
9. Use according to any preceding claim, wherein the peptide
comprises an amino acid sequence selected from the following
sequences: LysValIleProTyrValArgTyrLeu (SEQ. ID NO. 2);
ThrLysValIleProTyrValArgTyrLeu (SEQ. ID NO. 3);
LysThrLysValIleProTyrValArgTyrLeu (SEQ. ID NO. 4);
ProLysThrLysValIleProTyrValArgTyrLeu (SEQ. ID NO. 5):
GlnProLysThrLysValIleProTyrValArgTyrLeu (SEQ. ID NO. 6:
AlaMetLysProTrpIleGlnProLysThrLysValIleProTyrValArgTyrLeu (SEQ. ID
NO. 7);
ThrValTyrGlnHisGlnLysAlaMetLysProTrplleGinProLysThrLysValIleProTyrVa-
lArgTyr Leu (SEQ. ID NO. 8); and
ProGlnTyrLeuLysThrValTyrGlnHisGlnLysAlaMetLysProTrpIleGlnProLysThrLysValI-
le ProTyrValArgTyrLeu (SEQ. ID NO. 9).
10. Use according to any of claims 1-9, wherein the peptide
comprises an amino acid sequence selected from the following
sequences: LysValIleProTyr (SEQ. ID NO. 16); ThrLysValIleProTyr
(SEQ. ID NO. 17); LysThrLysValIleProTyr (SEQ. ID NO. 18);
ProLysThrLysValIleProTyr (SEQ. ID NO. 19);
GlnProLysThrLysValIleProTyr (SEQ. ID NO. 20);
AlaMetLysProTrpIleGlnProLysThrLysValIleProTyr (SEQ. ID NO. 21);
ThrValTyrGlnHisGInLysAlaMetLysProTrpIleGlnProLysThrLysValIleProTyr
(SEQ. ID NO. 22); and
ProGlnTyrLeuLysThrValTyrGlnHisGlnLysAlaMetLysProTrpIleGlnProLysThrLysValI-
le ProTyr (SEQ. ID NO. 23).
11. Use according to any preceding claim, wherein the peptide
comprises a peptide homologue in which: (a) one or more of the
amino acids Leu, Ile and Val are replaced by one another; and/or
(b) one or more of the amino acids Tyr and Phe are replaced by one
another; and/or (c) one or more of the amino acids Arg and Lys are
replaced by one another.
12. Use according to any of claims 4-1, wherein the effect of aging
is wrinkling of the skin.
13. Use according to any preceding claim, wherein the peptide is
capable of stimulating the growth of fibroblasts.
14. Use according to any preceding claim, wherein the peptide is
capable of stimulating fibroblasts to produce collagen.
15. Use according to any preceding claim, wherein the peptide is
capable of stimulating the growth of keratinocytes.
16. Use of a peptide, or a derivative of a peptide, in the
manufacture of a medicament effective in repairing and/or
maintaining the basement membrane zone of mammalian skin, wherein
the peptide comprises an amino acid sequence present in an
.alpha.-S2 casein precursor, said sequence comprising 3 or more
amino acids, and not comprising at its N-terminus the N-terminal
amino acid of the full .alpha.-S2 casein precursor.
17. Use of a peptide, or a derivative of a peptide, in the
manufacture of a medicament effective in repairing and/or
maintaining the basement membrane zone of mammalian skin, wherein
the peptide has an .alpha.-S2 casein fragment activity.
18. Use according to claim 16 or claim 17, wherein the medicament
is effective in alleviating or preventing periodontal disease.
19. Use according to claim 16 or claim 17, wherein the medicament
is effective in alleviating or preventing an effect of aging in
skin.
20. Use according to any of claims 16-19, wherein the mammal is a
human.
Description
[0001] The present invention relates to a protein, a peptide
(generally a polypeptide), a peptide derivative, or peptide
fragment which can be used to alleviate or prevent an effect-of
aging, particularly an effect of aging in skin, by stimulating the
production of fibrillin in fibroblasts. This may be in a method of
treatment or a cosmetic method. The invention also relates to the
same peptides, polypeptides, peptide derivatives or peptide
fragments which can be used as a prophylactic or treatment for
periodontal diseases (gum diseases) by stimulating the production
of fibrillin in fibroblasts. This may be in a medical method of
treatment if desired. In particular the invention relates to use of
a peptide which comprises an amino acid sequence from an .alpha.-S2
casein precursor.
[0002] For many years it has been known that, in addition to its
nutritional content, milk contains growth promoting activity for
cells. In this connection, epidermal growth factor (FGF) has been
identified in human (Shing and Klagsbrun, 1984; Petrides, 1985),
rat (Raaberg et al., 1990), swine (Tan et al., 1990) and goat
(Brown and Blakeley, 1983) milk. The EGF present in rat milk has
been shown to be significant for the normal development of rat pups
(Oka et al., 1983). EGF has not, however, been found in bovine milk
(Read 1985). Instead, insulin-like growth factor (IGF) I and II
(Francis et al., 1986) and bovine colostrum growth factor (BCGF),
which is structurally related to Platelet-derived Growth Factor
(PDGF) (Shing and Klagsbrun, 1984; Brown and Blakeley, 1994), have
been identified in bovine milk
[0003] In published International Application WO 97/16460 it is
disclosed that bovine milk contains growth promoting activity for a
rat mammary fibroblast cell line (Rama 27), which is not
significantly stimulated by IGF or PDGF. In this application
peptide sequences are identified which elicit this growth promoting
activity. These sequences are identified as sequences that are
substantially identical to the C-terminal end of bovine .alpha.-S2
casein precursor. The application indicates that these peptides or
salts thereof may be used for the manufacture of medicaments or
foodstuffs for promoting growth.
[0004] Published European Patent Application EP 0 457 565 discloses
milk protein hydrolysate and compositions for use in hair and skin
treatment. The proteins in the hydrolysate are not specifically
defined and have molecular weights of less than 1000 daltons. These
are thus very small hydrolysis products from a wide variety of
proteins present in milk
[0005] Published PCT Applications WO 92/00994, WO 95/29933 and WO
96/34614 disclose extracts from milk which may be used as growth
promoting agents and agents for treating alimentary tract damage.
The milk product extract may be from human or animal milk and
includes cheese whey extracts and skim-milk extracts. The documents
imply that IGF I or II are active ingredients giving the products
their utility, and do not indicate that the products should
comprise any specific protein.
[0006] In addition, topical applications, such as creams, have been
marketed that claim anti-aging efficacy for added Epidermal Growth
Factor (EGF) (Estee Lauder, advertised in Elle, 1999) and for `whey
proteins` (stee Lauder's `Diminish` in Martha Stewart's Living,
Feb, 2000). However, this efficacy has not been shown to be
especially high.
[0007] In published international application WO 02/02133, a
composition for treating periodontal disease and signs of aging in
skin is disclosed. This composition employs an a-S2 casein
precursor capable of stimulating the production of collagen in
fibroblasts.
[0008] It is an object of the present invention to solve the
problems associated with the prior art. In particular, it is an
object of the present invention to provide an agent capable of
alleviating or preventing the effects of aging in skin. It is also
an object of the invention to provide an agent capable of treating
or preventing periodontal disease. Surprisingly, the inventors have
found that an .alpha.-S2 casein precursor and related species, such
as those disclosed as growth promoters in WO 97/16460, are
extremely useful in alleviating and preventing the effects of aging
in skin, and in treating periodontal disease, by stimulating the
production of fibrillin in fibroblasts. The .alpha.-S2 casein
precursor and precursor fragments and derivatives used in the
present invention are superior to known anti-aging products and
products used for treating gum disease, and in particular to the
agents disclosed in the above prior art.
[0009] Accordingly, the present invention provides use of a
peptide, or a derivative of a peptide, in the manufacture of a
medicament effective in stimulating fibroblasts to produce
fibrillin, wherein the peptide comprises an amino acid sequence
present in an .alpha.-S2 casein precursor, said sequence comprising
3 or more amino acids, and not comprising at its N-terminus the
N-terminal amino acid of the full .alpha.-S2 casein precursor. The
invention also provides use of a peptide, or a derivative of a
peptide, in the manufacture of a medicament effective in
stimulating fibroblasts to produce fibrillin, wherein the peptide
has an .alpha.-S2 casein fragment activity. The medicament is
effective in alleviating or preventing periodontal disease and/or
in alleviating or preventing an effect of aging in skin, preferably
an effect of photoaging (damage or aging caused by exposure or
overexposure to UV light or sunlight).
[0010] The above-defined uses of the present invention include use
of the peptide, or its derivative, either in a pure form, or in a
partially purified form, such as that obtainable by isolation of
the peptide from a natural source. Thus, the present use may extend
to employment of the peptide in its natural unpurified form, such
as using a natural substance that comprises the peptide or its
derivative, or may involve use of the peptide or its derivative in
any level of purification, including entirely (100%) pure. The
peptide may also be from a proteolytic digest or a non-natural
source, such as a synthetic peptide. In the context of this
invention, the term peptide is intended to include proteins,
polypeptides and peptide fragments.
[0011] The present invention may be employed in a cosmetic and/or
medicinal method for alleviating or preventing an effect of aging
in skin, which method comprises treating a subject with a
polypeptide, or a derivative of a polypeptide, wherein the
polypeptide comprises an amino acid sequence present in an
.alpha.-S2 casein precursor, said sequence comprising 3 or more
amino acids, and not comprising the N-terminus of the full
.alpha.-S2 casein precursor.
[0012] To reiterate, the present inventors have surprisingly found
that a peptide comprising an amino acid sequence from an .alpha.-S2
casein precursor, and in particular a fragment of such a peptide,
has a very beneficial effect upon the skin, preventing and
alleviating many effects of aging, and treating and preventing
periodontal disease. The effect of these particular agents is
superior to the effect of prior art agents. By fragments, in the
context of the present invention it is meant any part of a sequence
from a protein, polypeptide or peptide that is not the full
sequence.
[0013] The invention will be further described by way of example
only with reference to the following drawings and specific
embodiments, in which:
[0014] FIG. 1 shows the result of a cation exchange column
chromatography experiment carried out on a dialysed cheese whey
salt-cut;
[0015] FIG. 2 shows the results of a hydrophobic interaction column
chromatography experiment performed on active fractions from cation
exchange chromatography,
[0016] FIG. 3 shows fibrillin production in ten human volunteers
treated with peptides of the present invention, compared with
occluded controls; and
[0017] FIG. 4 shows a corresponding pooled analysis of this
study.
[0018] In the context of the present invention, the effect of aging
may be any effect of aging. Thus the effect may be sagging of the
skin, wrinkling of the skin or slow regeneration of damaged areas
of skin. However, the effect is most preferably wrinkling of the
skin. The periodontal disease is a disease of the gums. In the
context of the present invention, this may be a gum disease arising
for any reason, including infection of the teeth or gums as well as
lack of cleaning (brushing or flossing) of the teeth or gums.
[0019] The polypeptide and polypeptide fragments used in the
present invention may have either an alleviating effect, or a
preventative effect, or both. Thus, they may have a prophylactic
effect and/or may reduce the effects of gum disease or of aging, or
provide protection against the onset of gum disease or may increase
the youthful appearance of the skin.
[0020] Whilst the whole .alpha.-S2 casein precursor shows no
significant efficacy against the effects of aging or gum disease,
fragments of such proteins, such as polypeptides derived from the
C-terminal end of .alpha.-S2 caseins, do have these effects. For
example, the efficacy against gum disease and effects of aging is
present in peptides which are derived from the C-terminal end of
.alpha.-S2 casein precursors and have 3 or more amino acids, but do
not comprise the N-terminal amino acid of the full .alpha.-S2
casein molecule. Thus, the casein-derived peptides and fragments
used in the present invention generally comprise 3 or more amino
acids and do not comprise the N-terminus of the full casein
protein. In the context of the present invention, the peptide not
comprising the N-terminal amino acid means that the peptide does
not comprise the N-terminal end (N-terminus) of the protein itself.
In some embodiments this can mean that the peptide does not
comprise a number of amino acids up to and including the
N-terminus. Preferably the peptides do comprise the C-terminus of
the-full protein.
[0021] Thus, the number of amino acids in the peptide or fragment
used the present invention is not especially limited, provided that
it has 3 or more amino acids, but does not comprise the N-terminal
end of the full casein. However, it is preferred that the number of
amino acids in the peptide is from 3-50, 4-50, 5-50, 6-50, or 7-50.
Advantageously, the number of amino acids may be from 8-50 and more
preferably from 9-50 or 10-50. It is particularly preferred that
the upper limit on the amino acids in all these cases is 35 and
most preferably 31. The most preferred number of amino acids is
from 9-31.
[0022] Thus, the peptide may preferably comprise the last 3-50,
3-35 or 3-31 amino acids of the C-terminal end of the .alpha.-S2
casein precursor (including the C-terminus) and may even be as
short as the last 3-10, 3-9,3-8 or 3-7 or even just the last 3
amino acids of the C-terminal end of the .alpha.-S2 casein.
[0023] The bovine .alpha.-S2 casein precursor used in the present
invention has the following amino acid sequence: [0024]
[CAS2_BOVIN] ALPHA-S2 CASEIN PRECURSOR
[0025] SEQUENCE: TABLE-US-00001 MKFFIFTCLL AVALAKNTME HVSSSEESII
SQETYKQEKN MAINPSKENL CSTFCKEVVR NANEEBYSIG SSSEESAEVA TEEVKITVDD
KHYQKALNEI NQFYQKFPQY LQYLYQGPIV LNPWDQVKRN AVPITPTLNR EQLSTSEENS
KKTVDMESTE VFTKKTKLTE EEKNRLNFLK KISQRYQKFA LPQYLKTVYQ HQKAMKLPWIQ
PKTKVIPYVR YL
[0026] In three letter codes this translates to: TABLE-US-00002 Met
Lys Phe Phe Ile Phe Thr Cys Leu Leu Ala Val Ala Leu Ala Lys Asn Thr
Met Glu His Val Ser Ser Ser Glu Glu Ser Ile Ile Ser Gln Glu Thr Tyr
Lys Gln Glu Lys Asn Met Ala Ile Asn Pro Ser Lys Glu Asn Leu Cys Ser
Thr Phe Cys Lys Glu Val Val Arg Asn Ala Asn Glu Glu Glu Tyr Ser Ile
Gly Ser Ser Ser Glu Glu Ser Ala Glu Val Ala Thr Glu Glu Val Lys Ile
Thr Val Asp Asp Lys His Tyr Gln Lys Ala Leu Asn Glu Ile Asn Gln Phe
Tyr Gln Lys Phe Pro Gln Tyr Leu Gln Tyr Leu Tyr Gln Gly Pro Ile Val
Leu Asn Pro Trp Asp Gln Val Lys Arg Asn Ala Val Pro Ile Thr Pro Thr
Leu Asn Arg Glu Gln Leu Ser Thr Ser Glu Glu Asn Ser Lys Lys Thr Val
Asp Met Glu Ser Thr Glu Val Phe Thr Lys Lys Thr Lys Leu Thr Glu Glu
Glu Lys Asn Arg Leu Asn Phe Leu Lys Lys Ile Ser Gln Arg Tyr Gln Lys
Phe Ala Leu Pro Gln Tyr Leu Lys Thr Val Tyr Gln His Gln Lys Ala Met
Lys Pro Trp Ile Gln Pro Lys Thr Lys Val Ile Pro Tyr Val Arg Tyr
Leu
[0027] It is preferred in the present invention that the peptide
comprises an amino acid sequence selected from the following
sequences: TABLE-US-00003 LysValIleProTyrValArgTyrLeu;
ThrLysValIleProTyrValArgTyrLeu; LysThrLysValIleProTyrValArgTyrLeu;
ProLysThrLysValIleProTyrValArgTyrLeu;
GlnProLysThrLysValIleProTyrValArgTyrLeu;
AlaMetLysProTrpIleGlnProLysThrLysValIleProTyrVal ArgTyrLeu;
ThrValTyrGlnHisGlnLysAlaMetLysProTrpIleGlnProLys
ThrLysValIleProTyrValArgTyrLeu; and
ProGlnTyrLeuLysThrValTyrGlnHisGlnLysAlaMetLysPro
TrpIleGlnProLysThrLysValIleProTyrValArgTyrLeu.
[0028] These sequences all comprise the last 9 amino acids of the
C-terminal end of the bovine .alpha.-S2 casein precursor. The
present inventors have found that peptide sequences incorporating
this C-terminal sequence, LysValIleProTyrVaLrgTyrLeu, show
particularly marked anti-aging activity. Thus in a particularly
preferred aspect of the present invention the polypeptide comprises
a bovine .alpha.-S2 casein fragment comprising the sequence
LysValIleProTyrValArgTyrLeu. Other particularly preferred sequences
referred to above include the last 10, 11, 12 and 13 amino acids of
the C-terminal end of the bovine .alpha.-S2 casein precursor. These
amino acids are also the same as the last 7 amino acids of the goat
and sheep .alpha.-S2 casein precursors, confirming the degree of
similarity between these proteins, particularly at their
C-termini
[0029] It is also preferred in the present invention that the
peptide comprises an amino acid sequence from the C-terminal end of
the bovine .alpha.-S2 casein precursor, but without the last four
C-terminal amino acids (i.e. without ValArgTyrLeu). Thus, the
following sequences are also preferred: TABLE-US-00004
LysValIleProTyr; ThrLysValIleProTyr; LysThrLysValIleProTyr;
ProLysThrLysValIleProTyr; GlnProLysThrLysValIleProTyr;
AlaMetLysProTrpIleGlnProLysThrLysValIleProTyr;
ThrValTyrGlnHisGlnLysAlaMetLysProTrpIleGlnProLys
ThrLysValIleProTyr; and
ProGlnTyrLeuLysThrValTyrGlnHisGlnLysAlaMetLysPro
TrpIleGlnProLysThrLysValIleProTyr.
[0030] As highlighted above, there is a high degree of homology
between the C-terminal end sequence of .alpha.-S2 casein precursors
of bovine, goat, sheep, rabbit and pig origin. It is apparent from
the sequences of these caseins that the C-terminal sequence can
vary from species to species, but that there are important
similarities. Accordingly, whilst bovine .alpha.-S2 casein
precursor fragments are preferred for use in the present invention,
goat, sheep, rabbit and-pig .alpha.-S2 casein fragments, or similar
fragments from other species, may also be employed if desired.
[0031] The sequences for .alpha.-S2 casein precursors of goat,
sheep, rabbit and pig origin are set out below. [0032] [CAS2 CAPH1]
.alpha.-S2 casein precursor (.alpha.-S2-CN)
[0033] SEQUENCE: TABLE-US-00005 MKFFIFTCLL AVALAKHKME HVSSSEEPIN
IFQEIYKQEK NMAIHPRKEK LCTTSCEEVV RNANEEEYSI RSSSEESAEV APEEIKITVD
DKHYQKALNE INQFYQKFPQ YLQYPYQGPI VLNPWDQVKR NAGPFTPTVN REQLSTSEEN
SKKTIDMEST EVFTKKTKLT EEEKNRLNFL KKISQYYQKF AWPQYLKTVD QHQKAMKPWT
QPKTNAIPYV RYL 223
[0034] >pir|S33881|S33881 .alpha.-S2 casein E--goat
[0035] SEQUENCE: TABLE-US-00006 MKFFIFTCLL AVALAKHKME HVSSSEEPIN
IFQEIYKQEK NMAIHPRKEK LCTTSCEEVV RNANEEEYSI RSSSEESAKV APEEIKITVD
DKHYQKALNE INQFYQKFPQ YLQYPYQGPI VLNPWDQVKR NAGPFTPTVN REQLSTSEEN
SKKTIDMEST EVFTKKTKLT EEEKNRLNFL KKISQYYQKF AWPQYLKTVD QHQKAMKPWT
QPKTNAIPYV RYL 223
[0036] .alpha.-S2 casein C--capra hircus
[0037] SEQUENCE: TABLE-US-00007 MKFFIFTCLL AVALAKHKME HVSSSEEPIN
IFQEIYKQEK NMAIHPRKEK LCTTSCEEVV RNANEEEYSI RSSSEESAEV APEEIKITVD
DKHYQKALNE INQFYQKFPQ YLQYPYQGPI VLNPWDQVKR NAGPFTPTVN REQLSTSEEN
SKKTIDMEST EVFTKKTKLT EEEKNRLNFL KKISQYYQKF AWPQYLKTVD QHQKAMKPWT
QPKTNAIPYV RYL 223
[0038] >pir|S39776|S39776 .alpha.-S2 casein form b
precursor--rabbit [0039] >gp|X76909|OCPAS2BCS.sub.--1
pre-.alpha.-S2b casein (AA-15 to 167) Oryctglagus cuniculus
[0040] SEQUENCE: TABLE-US-00008 MKFFIFTCLL AVALAKPKIE QSSEETIAV
SQEVSPNLEN ICSTACEEPI KNINEVEYVE VPTEIKDQEF YQKVNLLQYL QALYQYPTVM
DPWTRAETKA IPFIRTMQYK QEKDATKHTS QKTELTEEEK AFLKYLDEMK QYYQKFVFPQ
YLKNAHHFQK TMNPWNHVKT IIYQVPTSL 179
[0041] [CAS2_SHEEP] .alpha.-S2 casein precursor--sheep
[0042] SEQUENCE: TABLE-US-00009 MKFFIFTCLL AVALAKHKME HVSSSEEPIN
ISQEIYKQEK NMAIHPRKEK LCTTSCEEVV RNADEEEYSI RSSSEESAEV APEEVKITVD
DKHYQKALNE INQFYQKFPQ YLQYLYQGPI VLNPWDQVKR NAGPFTPTVN REQLSTSEEN
SKKTIDMEST EVFTKKTKLT EEEKNRLNFL KKISQYYQKF AWPQYLKTVD QHQKAMKPWT
QPKTNAIPYV RYL 223
[0043] [CAS2_PIG] .alpha.-S2 casein precursor--pig
[0044] SEQUENCE: TABLE-US-00010 MKFFIFTCLL AVAFAKHEME HVSSSEESIN
ISQEKYKQEK NVINHPSKED ICATSCEEAV RNIKEVGYAS SSSSEESVDI PAENVKVTVE
DKHYLKQLEK ISQFYQKFPQ YLQALYQAQI VMNPWDQTKT SAYPFIPTVI QSGEELSTSE
EPVSSSQEEN TKTVDESME EFTKKTELTE EEKNRIKFLN KIKQYYQKFT WFQYIKTVHQ
KQKAMKPWNH IKTNSYQIIP NLRYF 235
[0045] In three letter codes, these sequences translate to the
following. [0046] [CAS2 CAPH1] .alpha.-S2 casein precursor
(.alpha.-S2-CN)
[0047] SEQUENCE: TABLE-US-00011 Met Lys Phe Iie Phe Phe Thr Cys Leu
Leu Ala Val Ala Leu Ala Lys His Lys Met Glu His Val Ser Ser Ser Gly
Gly Pro Ile Asn Ile Phe Gln Glu Ile Tyr Lys Gln Glu Lys Asn Met Ala
Ile His Pro Arg Lys Glu Lys Leu Cys Thr Thr Ser Cys Glu Glu Val Val
Arg Asn Ala Asn Glu Glu Glu Tyr Ser Ile Arg Ser Ser Ser Glu Glu Ser
Ala Glu Val Ala Pro Glu Glu Ile Lys Ile Thr Val Asp Asp Lys His Tyr
Gln Lys Ala Leu Asn Glu Ile Asn Gln Phe Tyr Gln Lys Phe Pro Gln Tyr
Leu Gln Tyr Pro Tyr Gln Gly Pro Ile Val Leu Asn Pro Trp Asp Gln Val
Lys Arg Asn Ala Gly Pro Phe Thr Pro Thr Val Asn Arg Gln Gln Leu Ser
Thr Ser Glu Glu Asn Ser Lys Lys Thr Ile Asp Met Gln Ser Thr Glu Val
Phe Thr Lys Lys Thr Lys Leu Thr Gln Gln Glu Lys Asn Arg Leu Asn Phe
Leu Lys Lys Ile Ser Gln Tyr Tyr Gln Lys Phe Ala Trp Pro Gln Tyr Len
Lys Thr Val Asp Gln His Gln Lys Ala Met Lys Pro Trp Thr Gln Pro Lys
Thr Asn Ala Ile Pro Tyr Val Arg Tyr Leu
[0048] pir|S33881|S33881 .alpha.-S2 casein E--goat
[0049] SEQUENCE: TABLE-US-00012 Met Lys Phe Phe Ile Phe Thr Cys Leu
Leu Ala Val Ala Leu Ala Lys His Lys Met Glu His Val Ser Ser Ser Glu
Glu Pro Ile Asn Ile Phe Gln Glu Ile Tyr Lys Gln Glu Lys Asn Met Ala
Ile His Pro Arg Lys Glu Lys Leu Cys Thr Thr Ser Cys Glu Glu Val Val
Arg Asn Ala Asn Glu Glu Glu Tyr Ser Ile Arg Ser Ser Ser Glu Glu Ser
Ala Lys Val Ala Pro Glu Glu Ile Lys Ile Thr Val Asp Asp Lys His Tyr
Gln Lys Ala Leu Asn Glu Ile Asn Gln Phe Tyr Gln Lys Phe Pro Gln Tyr
Leu Gln Tyr Pro Tyr Gln Gly Pro Ile Val Leu Asn Pro Trp Asp Gln Val
Lys Arg Asn Ala Gly Pro Phe Thr Pro Thr Val Asn Arg Glu Gln Leu Ser
Thr Ser Glu Glu Asn Ser Lys Lys Thr Ile Asp Met Glu Set Thr Glu Val
Phe Thr Lys Lys Thr Lys Leu Thr Glu Glu Glu Lys Asn Arg Leu Asn Phe
Leu Lys Lys Ile Set Gln Tyr Tyr Gln Lys Phe Ala Trp Pro Gln Tyr Leu
Lys Thr Val Asp Gln His Gln Lys Ala Met Lys Pro Trp Thr Gln Pro Lys
Thr Asn Ala Ile Pro Tyr Val Arg Tyr Leu
[0050] >gp|S74171|S74171.sub.--1 .alpha.-S2 casein C--capra
hircus
[0051] SEQUENCE: TABLE-US-00013 Met Lys Phe Phe Ile Phe Thr Cys Leu
Leu Ala Val Ala Leu Ala Lys His Lys Met Glu His Val Ser Ser Ser Glu
Glu Pro Ile Asn Ile Phe Gln Glu Ile Tyr Lys Gln Glu Lys Asn Met Ala
Ile His Pro Arg Lys Glu Lys Leu Cys Thr Thr Ser Cys Glu Glu Val Val
Arg Asn Ala Asn Glu Glu Glu Tyr Ser Ile Arg Ser Ser Ser Glu Glu Ser
Ala Glu Val Asp Lys His Tyr Gln Lys Ala Leu Asn Glu Ile Asn Gln Phe
Tyr Gln Lys Phe Pro Gln Tyr Leu Gln Tyr Pro Tyr Gln Gly Pro Ile Val
Leu Asn Pro Trp Asp Gln Val Lys Arg Asn Ala Gly Pro Phe Thr Pro Thr
Val Asn Arg Glu Gln Leu Ser Thr Set Glu Glu Asn Ser Lys Lys Thr Ile
Asp Met Glu Ser Thr Glu Val Phe Thr Lys Lys Thr Lys Leu Thr Glu Glu
Glu Lys Asn Arg Leu Asn Phe Leu Lys Ile Ile Ser Gln Tyr Tyr Gln Lys
Phe Ala Trp Pro Gln Tyr Leu Lys Thr Val Asp Gln His Gln Lys Ala Met
Lys Pro Trp Thr Gln Pro Lys Thr Asn Ala Ile Pro Tyr Val Arg Tyr
Leu
[0052] >pir|S39776|S39776 .alpha.-S2 casein form b
precursor--rabbit [0053] >gp|X76909|OCPAS2BCS.sub.--1
pre-.alpha.-S2b casein (AA-15 to 167) Oryctolagus cuniculus
[0054] SEQUENCE: TABLE-US-00014 Met Lys Phe Phe Ile Phe Thr Cys Leu
Leu Ala Val Ala Leu Ala Lys Pro Lys Ile Glu Gln Ser Ser Ser Glu Glu
Thr Ile Ala Val Ser Gln Glu Val Ser Pro Asn Leu Glu Asn Ile Cys Ser
Thr Ala Cys Glu Glu Pro Ile Lys Asn Ile Asn Glu Val Glu Tyr Val Glu
Val Pro Thr Glu Ile Lys Asp Gln Glu Phe Tyr Gln Lys Val Asn Leu Leu
Gln Tyr Leu Gln Ala Leu Tyr Gln Tyr Pro Thr Val Met Asp Pro Trp Thr
Arg Ala Glu Thr Lys Ala Ile Pro Phe Ile Arg Thr Met Gln Tyr Lys Gln
Glu Lys Asp Ala Thr Lys His Thr Ser Gln Lys Thr Glu Leu Thr Glu Glu
Glu Lys Ala Phe Leu Lys Tyr Leu Asp Glu Met Lys Gln Tyr Tyr Gln Lys
Phe Val Phe Pro Gln Tyr Leu Lys Asn Ala His His Phe Gln Lys Thr Met
Asn Pro Trp Asn His Val Lys Thr Ile Ile Tyr Gln Set Val Pro Thr
Leu
[0055] [CAS2_SHEEP] .alpha.-S2 casein precursor--sheep
[0056] SEQUENCE: TABLE-US-00015 Met Lys Phe Phe Ile Phe Thr Cys Leu
Leu Ala Val Ala Leu Ala Lys His Lys Met Glu His Val Ser Ser Ser Glu
Glu Pro Ile Asn Ile Ser Gln Glu Ile Tyr Lys Gln Glu Lys Asn Met Ala
Ile His Pro Arg Lys Glu Lys Leu Cys Thr Thr Ser Cys Glu Glu Val Val
Arg Asn Ala Asp Glu Glu Glu Tyr Ser Ile Arg Ser Ser Ser Glu Glu Ser
Ala Glu Val Ala Pro Glu Glu Val Lys Ile Thr Val Asp Asp Lys His Tyr
Gln Lys Ala Leu Asn Glu Ile Asn Gln Phe Tyr Gln Lys Phe Pro Gln Tyr
Leu Gln Tyr Leu Tyr Gln Gly Pro Ile Val Leu Asn Pro Trp Asp Gln Val
Lys Arg Asn Ala Gly Pro Phe Thr Pro Thr Val Asn Arg Glu Gln Leu Ser
Thr Ser Glu Glu Asn Ser Lys Lys Thr Ile Asp Met Glu Ser Thr Glu Val
Phe Thr Lys Lys Thr Lys Leu Thr Glu Glu Glu Lys Asn Arg Leu Asn Phe
Leu Lys Lys Ile Ser Gln Tyr Tyr Gln Lys Phe Ala Trp Pro Gln Tyr Leu
Lys Thr Val Asp Gln His Gln Lys Ala Met Lys Pro Trp Thr Gln Pro Lys
Thr Asn Ala Ile Pro Tyr Val Arg Tyr Leu
[0057] [CAS2 PIG] .alpha.-S2 casein precursor--pig
[0058] SEQUENCE: TABLE-US-00016 Met Lys Phe Phe Ile Phe Thr Cys Leu
Leu Ala Val Ala Phe Ala Lys His Glu Met Glu His Val Ser Ser Ser Glu
Glu Ser Ile Asp Ile Ser Gln Glu Lys Tyr Lys Gln Glu Lys Asn Val Ile
Asn His Pro Ser Lys Glu Asp Ile Cys Ala Thr Ser Cys Glu Glu Ala Val
Arg Asn Ile Lys Glu Val Glu Tyr Ala Ser Ser Ser Ser Ser Glu Glu Ser
Val Asp Ile Pro Ala Glu Asn Val Lys Val Thr Val Glu Asp Lys His Tyr
Leu Lys Gln Leu Glu Lys Ile Ser Gln Phe Tyr Gln Lys Phe Pro Gln Tyr
Leu Gln Ala Leu Tyr Gln Ala Gln Ile Val Met Asn Pro Trp Asp Gln Thr
Lys Thr Ser Ala Tyr Pro Phe Ile Pro Thr Val Ile Gln Ser Gly Glu Glu
Leu Ser Thr Ser Glu Glu Pro Val Ser Ser Ser Gln Glu Glu Asn Thr Lys
Thr Val Asp Met Glu Ser Met Glu Glu Phe Thr Lys Lys Thr Glu Leu Thr
Glu Glu Glu Lys Asn Arg Ile Lys Phe Leu Asn Lys Ile Lys Gln Tyr Tyr
Gln Lys Phe Thr Trp Pro Gln Tyr Ile Lys Thr Val His Gln Lys Gln Lys
Ala Met Lys Pro Trp Asn His Ile Lys Thr Asn Ser Tyr Gln Ile Ile Pro
Asn Leu Arg Tyr Phe
[0059] Furthermore, due to the similar nature of some amino acids
it is possible to interchange some amino acids without affecting
the functioning of the sequence. Accordingly leucine, isoleucine
and valine may be interchanged. In addition tyrosine and
phenylalanine may also be interchanged, as may arginine and
lysine.
[0060] The invention will now be discussed in more detail. The
invention preferably relates to .alpha.-S2 casein precursor
fragments, and more preferably to the peptides referred to in WO
97/16460, for use as a cosmetic product, preferably in a cream or
lotion, for reducing an aging effect in skin, such as wrinkles. The
invention is preferably applicable to human skin, but may if
desired be applied to other skin such as mammalian skin
generally.
[0061] The invention also relates to the .alpha.-S2 casein
precursor fragments mentioned above for use as a prophylactic agent
or treatment agent for periodontal disease. This preferably relates
to such diseases in humans, but may also apply to such diseases in
mammalian gums generally if desired. The agent may be in any
suitable form, such as a topical agent (e.g. a toothpaste for
cleaning the teeth and/or gums) or a chewing gum.
[0062] The peptides may be used as a pure product, or may
conveniently be supplied as an enriched natural preparation from
milk by following the protocols described in WO 97/16460 as far as
(and including) the hydrophobic interaction chromatography step.
Alternatively, cheese whey may be used in place of the acid (milk)
whey.
[0063] The peptides may be used alone, or in combination with
acceptable (in some cases pharmaceutically acceptable) additives
and/or excipients useful for formulating topical compositions,
toothpastes, or chewing gums. Additives for topical agents may
include, for example, moisturising agents and/or other agents
beneficial to the skin, such as all or any of vitamins A, C, D and
E, that are used to beneficial effect to prevent/reverse the aging
of skin.
[0064] Without being bound by theory, it is believed that the basis
of the invention is that the peptides stimulate the production of
fibrillin in fibroblasts, especially dermal fibroblasts. This is
believed to ameliorate the fibrillin-rich microfibrillar network
proximal to the dermal-epidermal junction of aged skin. Thus the
peptides are capable of repairing the fibrillin deficit in aged
(especially photoaged) skin.
[0065] The peptides used in the present invention appear to fulfil
the equivalent role in bovine milk that EGF does in other species.
The present inventors have surprisingly discovered that these
peptides are effective as anti-periodontal disease agents and
anti-aging agents and are more effective than known products. A
further advantage of the peptides used in the present invention is
that whilst they have an efficacy similar to, or are superior to,
EGF they are regarded as being `natural products` (being
milk-derived) and because they have essentially no full protein
content, they are not allergenic.
[0066] In the present invention the peptide, or derivative of the
peptide, can be used in the manufacture of a medicament effective
in alleviating or preventing an effect of aging in ski, wherein the
peptide has an .alpha.-S2 casein fragment activity. Thus the
peptide may be an .alpha.-S2 casein precursor fragment, as
described in detail above, or ca be a related molecule having a
similar activity, such as a homologue. The peptides are
particularly effective against photoaging. In the present context,
photoaging of skin means the effects of cumulative exposure to
ultra-violet radiation and/or sunlight, or alternatively the
combination of chronological ageing and the effects of cumulative
exposure to ultra-violet radiation and/or sunlight. Typically, it
is manifested clinically by coarse and fine wrinkling,
dyspigmentation, sallowness and the formation of benign and
malignant neoplasms. The mechanisms of wrinkle formation are not
fully understood, but without being bound by theory, it is thought
that the glycoprotein fibrillin may be important. Fibrillin is a
major constituent of the elastin network in the papillary dermis
and plays an important role in maintaining the integrity of the
basement membrane zone. The present invention relates to methods of
repairing the basement membrane zone, by stimulating the production
of fibrillin.
[0067] Also in the present invention, the peptide, or derivative of
the peptide, can be used in the manufacture of a medicament
effective in alleviating or preventing periodontal disease, wherein
the peptide has an .alpha.-S2 casein fragment activity. Thus, as in
the related aspect, the peptide may be an .alpha.-S2 casein
precursor fragment, as described in detail above, or can be a
related molecule having a similar activity, such as a
homologue.
[0068] Preferably the peptide used in the present invention is
capable of stimulating the growth of fibroblasts. It is also
preferred that the peptide is capable of stimulating fibroblasts to
produce collagen. It is further preferred that the peptide is
capable of stimulating growth in keratinocytes.
[0069] In a further aspect, the present invention provides a
cosmetic method, or a medical method, for alleviating or preventing
an effect of aging in skin by stimulating the production of
fibrillin in fibroblasts, which method comprises treating a subject
with a peptide, wherein the peptide comprises an amino acid
sequence present in an .alpha.-S2 casein precursor, said sequence
comprising 3 or more amino acids, and not comprising at its
N-terminus the N-terminal amino acid of the full .alpha.-S2 casein
precursor. The peptide is preferably a specific peptide as
discussed in detail above, but alternatively may be an .alpha.-S2
casein precursor fragment, or a related molecule having a similar
activity, such as a homologue.
[0070] In a still further aspect, the present invention provides a
topical composition for stimulating the production of fibrillin by
fibroblasts, comprising a peptide, or a derivative of a peptide,
wherein the peptide comprises an amino acid sequence present in an
x-S2 casein precursor, said sequence comprising 3 or more amino
acids, and not comprising at its N-terminus the N-terminal amino
acid of the full .alpha.-S2 casein precursor. The peptide is
preferably a specific peptide as discussed in detail above, but
alternatively may be an .alpha.-S2 casein precursor fragment, or a
related molecule having a similar activity, such as a
homologue.
[0071] In a related aspect, the invention provides a pharmaceutical
composition for alleviating or preventing periodontal disease by
stimulating the production of fibrillin by fibroblasts, comprising
a peptide, or a derivative of a peptide, wherein the peptide
comprises an amino acid sequence present in an .alpha.-S2 casein
precursor, said sequence comprising 3 or more amino acids, and not
comprising at its N-terminus the N-terminal amino acid of the full
.alpha.-S2 casein precursor. Again, the peptide is preferably a
specific peptide as discussed in detail above, but alternatively
may be an .alpha.-S2 casein precursor fragment, or a related
molecule having a similar activity, such as a homologue.
[0072] The invention will be further described by way of example
only with reference to the following specific embodiments.
EXAMPLES
Example 1
Preparation of Standardised Natural Product from Cheese Whey
[0073] This procedure covers the methods for the collection,
preparation and storage of Standardised Natural Product (SNP) from
cheese whey. Typically, this procedure is used for small-scale
preparation of SNP, such as for research and development purposes.
However, the procedure can be scaled up as desired for commercial
production according to known techniques.
Collection and Storage of Cheese Whey
[0074] Approximately 401 of fresh clarified cheese whey was
obtained from DewLay cheese manufacturing plant (Garstang,
Lancashire). The whey was collected in clean containers and
immediately transported to Pepsyn Central Manufacturing Facility
(Liverpool).
[0075] Whey was either refrigerated for processing the following
day or the whey was frozen at -20.degree. C. in shallow 21
containers until required.
Thawing of Cheese Whey
[0076] Frozen whey was thawed by placing a 2 l block of whey in a
plastic bag and immersing it in hot running water. Thawing was
completed in less than 10 mins and the temperature of the melting
whey was maintained below 10.degree. C.
Salting Out
[0077] The pH of the whey was adjusted to 3.0 using concentrated
HCl. To each litre of whey, 220 g of (NH4).sub.2SO.sub.4 (BDH,
AnalaR grade) was slowly added over a period of 30 mins whilst
stirring. It was left to equilibrate for a further 1 hr 30 mins
without stirring, and then centrifuged at 9000 rpm for 40 mins
using a SorvallRC-5B centrifuge and associated GS-3 rotor (DuPont
Instruments), which were pre-equilibrated to an operating
temperature of between 4 and 10.degree. C. To each litre of
supernatant recovered, 130 g of (NH.sub.4).sub.2SO.sub.4 was added,
and left to equilibrate and centrifuged as described above. The
supernatant was discarded and the pellet was redissolved in
distilled water (400 ml for each litre of whey started with). This
was dialysed with visking tubing MWCO 12,000 to 14,000 daltons
(Medicell Int. Ltd, UK) against running tap water overnight and
then with 20 mM sodium phosphate buffer at pH 6.0 for 7 hr with one
change of buffer. The dialysed salt-cut was collected and either
refrigerated for processing the following day or frozen
(-20.degree. C.) until required.
Cation Exchange Chromatography
[0078] Dialysed cheese whey salt-cut was run on cation-exchange
chromatography, at 4.degree. C. with a mobile phase of 20 mM sodium
phosphate buffer, pH 6.0. Protein was eluted using a linear salt
gradient of 100 to 700 mM NaCl provided by a gradient mixer
(Pharmacia gradient mixer GM-1). The progress of the run was
monitored at 280 nm using a UV monitor (Uvicord S II,
Pharmacia).
[0079] A cation exchange column (Pharmacia XK50series, 50 mm i.d.)
was prepared with CM52 carboxymethyl (Whatman) to a packed bed
height of 15 cm. This was equilibrated with 500 ml of buffer
solution. Dialysed cheese whey salt cut (400 ml) was loaded on the
column at a flow rate of 2.5 ml/min and then washed overnight with
500 ml of 50 mM NaCl in buffer at a flow rate of about 0.5 ml/min.
A 500 ml linear gradient of 100 to 700 mM NaCl in buffer was
applied at a 2.0 ml/min and fractions were collected every 25 ml
and numbered sequentially. The column was then washed with 300 ml
of 2M NaCl in buffer. Collected fractions were tested for growth
promoting activity. This was typically observed in fraction numbers
11 and 12 that contained lactoferrin, and also in the fractions
just before and after these (see FIG. 1). Because lactoferrin gave
a brown appearance to the fractions then this was used as a visual
marker for activity. The mean estimated concentration of NaCl in
each of the collected fractions is given in Table 1. All fractions
were frozen until required for the next chromatographic step.
TABLE-US-00017 TABLE 1 Concentration of NaCl in each fraction from
CM52 run. Fraction Estimated NaCl (mM) 5 115 6 145 7 175 8 205 9
235 10 265 11 295 12 325 13 355 14 385 15 415 16 445 17 475 18 505
19 535 20 565 21 595 22 625 23 655 24 685 N.B. Between the column
inlet and outlet there was approximately 100 ml excluded volume.
Therefore fraction 1 to 4 contained 50 mM NaCl from the wash
buffer.
Hydrophobic Interaction Chromatography
[0080] Active fractions from cation exchange chromatography were
run on hydrophobic interaction chromatography (HIC). This was
performed at room temperature with a mobile phase of 20 mM sodium
phosphate buffer at pH 6.5. Protein was eluted using a linear salt
gradient of 4 to 0 M NaCl provided by a gradient mixer (Pharmacia
gradient mixer GM-1). The progress of the run was monitored at 280
nm using a UV monitor (Uvicord S II, Pharmacia).
[0081] A HIC column (Pharmacia C series, 26 mm i.d.) was prepared
with Butyl Sepharose 4 Fast Flow (Pharmacia) to give a packed bed
height of 15 cm. The column was equilibrated overnight with 250 ml
of 4 M NaCl in buffer at a flow rate of 0.25 ml/min.
[0082] The active fractions from several cation exchange
chromatography runs were pooled together to give between 100 and
200 ml of sample. The means concentration of NaCl in this sample
was calculated from the estimated concentrations of NaCl in the
constituent fractions (Table 1). Solid NaCl was then slowly added
to the sample to make it 3.7 M, and the pH was adjusted to 6.5.
Sample was loaded on the column added to 2.0 ml/min. A 500 ml
eluting gradient of 4 M to 0 M NaCl was applied and fractions were
collected every 25 ml and numbered sequentially. The column was
then washed with 250 ml of buffer followed by 250 ml of water.
[0083] Collected fractions were tested for growth promoting
activity. This was typically observed in fraction numbers 10 to 13,
which were the fractions that eluted just before the brown
lactoferrin fractions (see FIG. 2). Active fractions were pooled,
extensively dialysed against distilled water and freeze-dried.
Example 2
Demonstration that SNP Increases Fibrillin Synthesis In Vivo in
Humans
[0084] This Example shows that the peptides employed in the present
invention stimulate the replacement of fibrillin in vivo, aiding in
the repair of skin that has been photoaged. The peptides thus have
clinical efficacy.
[0085] The study involves a topical application of casein peptides
(36 .mu.g SNP/ml of water; SNP was produced in accordance with
Example 1) to determine the change in the expression of fibrillin
and pro-collagen I in photoaged skin. Occlusion-only controls were
also studied.
Patch-Test Control
[0086] Ten healthy, but photoaged, volunteers were recruited (male:
7; female: 3; age range 37-77 years). Test substances were applied
separately under standard 6 mm diameter Finn chambers to the
extensor aspect of the forearm; these were casein peptides (36
.mu.g SNP/ml water), and occluded baseline control. After treatment
for 4 days the Finn chambers were removed, and a 3 mm punch biopsy
was be obtained under 1 vol. % lignocaine anaesthesia from each
test site. Each biopsy was snap frozen in liquid nitrogen and
processed histological assessment. Biopsy sites were sutured with
1.times.4/o ethilon and subjects instructed to return in 74 days
for suture removal.
Fibrillin Examination by Immunohistochemistry
[0087] Frozen sections were prepared at a thickness of 10 .mu.m
(OTF cryostat, Bright Instruments Ltd.). Three sections per area
per patient were treated as follows to identify the fibrillin-rich
microfibrillar network by light microscopy:
[0088] Sections were fixed with 4 vol. % paraformaldehyde in
phosphate-buffered saline (10 mins). Following hydration in
tris-buffered saline (TBS; 100 mM Tris, 150 mM NaCl), sections were
solubilised by addition of 0.5 vol. % Triton-X 100.RTM. (10 mins).
Following washing, endogenous peroxidase activity was abolished by
incubation with an excess of hydrogen peroxide in methanol (30
mins). All sections were then blocked with 1 vol. % normal horse
serum+1 vol. % bovine serum albumen, prior to application of
primary antibody (mouse anti-human fibrillin-1, clone 11C1.3;
NeoMarkers, Calif., USA) at a dilution of 1:100. Negative controls
were concurrently incubated with either block alone or control
mouse serum at a dilution of 1:100. Following incubation, sections
were stringently washed with TBS prior to application of the horse
anti-mouse IgG biotinylated secondary antibody. This was further
conjugated to the enzyme horseradish peroxidase using a
commercially available kit following the manufacturers instructions
(ABC Elite System, Vector Laboratory, Peterborough UK). Antibody
was localised using 3',3'-diaminobenzadine as chromogen (10 mins
incubation). Washing in TBS quenched this reaction. Sections were
counterstained using nuclear fast red and finally dehydrated
through serial alcohols, cleared and permanently mounted.
[0089] Sections were randomised, blinded and examined on a Nikon
OPTIPHOT microscope (Tokyo, Japan). The degree of immunostaining
was assessed on a 5 point semi-quantitative scale where 0=no
staining and 4=maximal sing. Four sections (including control) were
examined per subject per site. The degree of immunostaining was
scored for three high power fields per section, and the average
score calculated for each site/test area.
[0090] Differences in the distribution of fibrillin protein between
the test sites, and after application of test substances for
varying periods of time, were assessed for significance using the
analysis of variance test (ANOVA; SPSS+v10.0, SPSS Inc., IL
USA).
[0091] The majority of volunteers tolerated the casein patch test
protocol well; of the 10, only one individual complained of
tenderness at the site of the casein application. The casein
peptide patch produced deposition of fibrillin-1 proximal to the
dermal/epidermal junction (base membrane zone) in 7/10 individuals
(the volunteer who had complained of tenderness was amongst the 3
"non-responders" in this trial).
[0092] A known agent for stimulating fibrillin production is
all-trans retinoic acid (RA). However, a drawback of this agent is
that it produces marked erythema at the site of application. None
of the above subjects produced erythema following application of
casein, showing the advantage of this agent over all-trans retinoic
acid.
[0093] Individual performance data is shown in FIG. 3. The mean
data per volunteer was then pooled and is shown graphically in FIG.
4; all data is presented as means.+-.SEM. In brief, it was found
that casein had a very positive effect on the fibrillin-rich
microfibrillar network of the papillary dermis over that of
baseline (occluded: 0.93=0.21; casein: 1.86=0.39; p=0.023).
[0094] From this Example it can be seen that topical application of
casein peptides (under occlusion) ameliorates the fibrillin-rich
microfibrillar network proximal to the dermal-epidermal junction of
photoaged skin. These results show that casein peptides used in the
present invention can repair the fibrillin deficit in photoaged
skin and/or aged skin, and have clear clinical utility.
Example 3
Demonstration that SNP Increases Collagen Synthesis in
Fibroblasts
[0095] Rama 27 rat mammary cells were grown to confluence, and
their rate of synthesis of collagen was measured using the method
of M. J. Warburton, S. A. Ferns, and P. S. Rudland, Experimental
Cell Research, 137, 373-380 (1982). The rates of collagen synthesis
as estimated by the incorporation of [3H]proline into
hydroxyproline are set out in Table 2 below: TABLE-US-00018 TABLE 2
Rates of collagen synthesis Concentration of SNP Cellular
HO-proline Secreted HO-proline (mg/ml) (cpm) (cpm) 0 53 54 0.2 271
233 0.4 232 327 0.6 321 663
[0096] Adding up to 0.6 mg/ml of SNP gives rise to an approximate
12-fold increase in the secretion of collagen--from 54 cpm to 663
cpm. This also gives rise to an approximate doubling in the ratio
of synthesised collagen that is secreted to that which is retained
in the cell--from 54:53 (1:1) to 663:321 (2:1).
Example 4
Demonstration of the Effect of SNP on the Growth of
Keratinocytes
[0097] Human keratinocytes (HatKat) were grown in keratinocyte
growth medium (TCS Cellworks Ltd.) until 20% confluence. Then, in
the same medium, the keratinocytes were grown for three days with
0.5% foetal calf serum (FCS), at which point the cells were counted
in a Coulter.RTM. counter. The cell numbers obtained are set out in
Table 3 below. TABLE-US-00019 TABLE 3 Cell numbers Conditions of
growth Number of cells Medium with 0.5% FCS 23,777 Medium with 0.5%
FCS + 10 ng/ml EGF 29,356 Medium with 0.5% FCS + 0.6 mg/ml SNP
68,719
[0098] This shows that the presence of SNP gives rise to an
approximate 3-fold increase in the growth of keratinocytes--from
23,777 to 68,719. This compares with a relatively modest increase
with the use of 10 ng/ml EGF.
[0099] These results clearly demonstrate the collagen producing
activity and growth promoting activity of the peptides used in the
present invention.
Sequence CWU 1
1
23 1 222 PRT Bos taurus PROPEP (1)..(222) Amino acid sequence of
bovine alpha-S2 casein precursor. 1 Met Lys Phe Phe Ile Phe Thr Cys
Leu Leu Ala Val Ala Leu Ala Lys 1 5 10 15 Asn Thr Met Glu His Val
Ser Ser Ser Glu Glu Ser Ile Ile Ser Gln 20 25 30 Glu Thr Tyr Lys
Gln Glu Lys Asn Met Ala Ile Asn Pro Ser Lys Glu 35 40 45 Asn Leu
Cys Ser Thr Phe Cys Lys Glu Val Val Arg Asn Ala Asn Glu 50 55 60
Glu Glu Tyr Ser Ile Gly Ser Ser Ser Glu Glu Ser Ala Glu Val Ala 65
70 75 80 Thr Glu Glu Val Lys Ile Thr Val Asp Asp Lys His Tyr Gln
Lys Ala 85 90 95 Leu Asn Glu Ile Asn Gln Phe Tyr Gln Lys Phe Pro
Gln Tyr Leu Gln 100 105 110 Tyr Leu Tyr Gln Gly Pro Ile Val Leu Asn
Pro Trp Asp Gln Val Lys 115 120 125 Arg Asn Ala Val Pro Ile Thr Pro
Thr Leu Asn Arg Glu Gln Leu Ser 130 135 140 Thr Ser Glu Glu Asn Ser
Lys Lys Thr Val Asp Met Glu Ser Thr Glu 145 150 155 160 Val Phe Thr
Lys Lys Thr Lys Leu Thr Glu Glu Glu Lys Asn Arg Leu 165 170 175 Asn
Phe Leu Lys Lys Ile Ser Gln Arg Tyr Gln Lys Phe Ala Leu Pro 180 185
190 Gln Tyr Leu Lys Thr Val Tyr Gln His Gln Lys Ala Met Lys Pro Trp
195 200 205 Ile Gln Pro Lys Thr Lys Val Ile Pro Tyr Val Arg Tyr Leu
210 215 220 2 9 PRT Bos taurus PEPTIDE (1)..(9) Amino acid sequence
of peptide derived from bovine alpha-2 casein precursor. 2 Lys Val
Ile Pro Tyr Val Arg Tyr Leu 1 5 3 10 PRT Bos taurus PEPTIDE
(1)..(10) Amino acid sequence of peptide derived from bovine
alpha-2 casein precursor. 3 Thr Lys Val Ile Pro Tyr Val Arg Tyr Leu
1 5 10 4 11 PRT Bos taurus PEPTIDE (1)..(11) Amino acid sequence of
peptide derived from bovine alpha-2 casein precursor. 4 Lys Thr Lys
Val Ile Pro Tyr Val Arg Tyr Leu 1 5 10 5 12 PRT Bos taurus PEPTIDE
(1)..(12) Amino acid sequence of peptide derived from bovine
alpha-2 casein precursor. 5 Pro Lys Thr Lys Val Ile Pro Tyr Val Arg
Tyr Leu 1 5 10 6 13 PRT Bos taurus PEPTIDE (1)..(13) Amino acid
seuqence of peptide derived from bovine alpha-2 casein precursor. 6
Gln Pro Lys Thr Lys Val Ile Pro Tyr Val Arg Tyr Leu 1 5 10 7 19 PRT
Bos taurus PEPTIDE (1)..(19) Amino acid sequence of peptide derived
from bovine alpha-S2 casein precursor. 7 Ala Met Lys Pro Trp Ile
Gln Pro Lys Thr Lys Val Ile Pro Tyr Val 1 5 10 15 Arg Tyr Leu 8 26
PRT Bos taurus PEPTIDE (1)..(26) Amino acid of peptide derived from
bovine alpha-S2 casein precursor 8 Thr Val Tyr Gln His Gln Lys Ala
Met Lys Pro Trp Ile Gln Pro Lys 1 5 10 15 Thr Lys Val Ile Pro Tyr
Val Arg Tyr Leu 20 25 9 31 PRT Bos taurus PEPTIDE (1)..(31) Amino
acid of peptide derived from bovine alpha-S2 casein precursor. 9
Pro Gln Tyr Leu Lys Thr Val Tyr Gln His Gln Lys Ala Met Lys Pro 1 5
10 15 Trp Ile Gln Pro Lys Thr Lys Val Ile Pro Tyr Val Arg Tyr Leu
20 25 30 10 223 PRT Capra hircus PROPEP (1)..(223) Amino acid
sequence of goat alpha-S2 casein precursor. 10 Met Lys Phe Phe Ile
Phe Thr Cys Leu Leu Ala Val Ala Leu Ala Lys 1 5 10 15 His Lys Met
Glu His Val Ser Ser Ser Glu Glu Pro Ile Asn Ile Phe 20 25 30 Gln
Glu Ile Tyr Lys Gln Glu Lys Asn Met Ala Ile His Pro Arg Lys 35 40
45 Glu Lys Leu Cys Thr Thr Ser Cys Glu Glu Val Val Arg Asn Ala Asn
50 55 60 Glu Glu Glu Tyr Ser Ile Arg Ser Ser Ser Glu Glu Ser Ala
Glu Val 65 70 75 80 Ala Pro Glu Glu Ile Lys Ile Thr Val Asp Asp Lys
His Tyr Gln Lys 85 90 95 Ala Leu Asn Glu Ile Asn Gln Phe Tyr Gln
Lys Phe Pro Gln Tyr Leu 100 105 110 Gln Tyr Pro Tyr Gln Gly Pro Ile
Val Leu Asn Pro Trp Asp Gln Val 115 120 125 Lys Arg Asn Ala Gly Pro
Phe Thr Pro Thr Val Asn Arg Glu Gln Leu 130 135 140 Ser Thr Ser Glu
Glu Asn Ser Lys Lys Thr Ile Asp Met Glu Ser Thr 145 150 155 160 Glu
Val Phe Thr Lys Lys Thr Lys Leu Thr Glu Glu Glu Lys Asn Arg 165 170
175 Leu Asn Phe Leu Lys Lys Ile Ser Gln Tyr Tyr Gln Lys Phe Ala Trp
180 185 190 Pro Gln Tyr Leu Lys Thr Val Asp Gln His Gln Lys Ala Met
Lys Pro 195 200 205 Trp Thr Gln Pro Lys Thr Asn Ala Ile Pro Tyr Val
Arg Tyr Leu 210 215 220 11 223 PRT Capra hircus DOMAIN (1)..(223)
Amino acid sequence of goat alpha-S2 casein E. 11 Met Lys Phe Phe
Ile Phe Thr Cys Leu Leu Ala Val Ala Leu Ala Lys 1 5 10 15 His Lys
Met Glu His Val Ser Ser Ser Glu Glu Pro Ile Asn Ile Phe 20 25 30
Gln Glu Ile Tyr Lys Gln Glu Lys Asn Met Ala Ile His Pro Arg Lys 35
40 45 Glu Lys Leu Cys Thr Thr Ser Cys Glu Glu Val Val Arg Asn Ala
Asn 50 55 60 Glu Glu Glu Tyr Ser Ile Arg Ser Ser Ser Glu Glu Ser
Ala Lys Val 65 70 75 80 Ala Pro Glu Glu Ile Lys Ile Thr Val Asp Asp
Lys His Tyr Gln Lys 85 90 95 Ala Leu Asn Glu Ile Asn Gln Phe Tyr
Gln Lys Phe Pro Gln Tyr Leu 100 105 110 Gln Tyr Pro Tyr Gln Gly Pro
Ile Val Leu Asn Pro Trp Asp Gln Val 115 120 125 Lys Arg Asn Ala Gly
Pro Phe Thr Pro Thr Val Asn Arg Glu Gln Leu 130 135 140 Ser Thr Ser
Glu Glu Asn Ser Lys Lys Thr Ile Asp Met Glu Ser Thr 145 150 155 160
Glu Val Phe Thr Lys Lys Thr Lys Leu Thr Glu Glu Glu Lys Asn Arg 165
170 175 Leu Asn Phe Leu Lys Lys Ile Ser Gln Tyr Tyr Gln Lys Phe Ala
Trp 180 185 190 Pro Gln Tyr Leu Lys Thr Val Asp Gln His Gln Lys Ala
Met Lys Pro 195 200 205 Trp Thr Gln Pro Lys Thr Asn Ala Ile Pro Tyr
Val Arg Tyr Leu 210 215 220 12 223 PRT Capra hircus DOMAIN
(1)..(223) Amino acid sequence of goat alpha-S2 casein C. 12 Met
Lys Phe Phe Ile Phe Thr Cys Leu Leu Ala Val Ala Leu Ala Lys 1 5 10
15 His Lys Met Glu His Val Ser Ser Ser Glu Glu Pro Ile Asn Ile Phe
20 25 30 Gln Glu Ile Tyr Lys Gln Glu Lys Asn Met Ala Ile His Pro
Arg Lys 35 40 45 Glu Lys Leu Cys Thr Thr Ser Cys Glu Glu Val Val
Arg Asn Ala Asn 50 55 60 Glu Glu Glu Tyr Ser Ile Arg Ser Ser Ser
Glu Glu Ser Ala Glu Val 65 70 75 80 Ala Pro Glu Glu Ile Lys Ile Thr
Val Asp Asp Lys His Tyr Gln Lys 85 90 95 Ala Leu Asn Glu Ile Asn
Gln Phe Tyr Gln Lys Phe Pro Gln Tyr Leu 100 105 110 Gln Tyr Pro Tyr
Gln Gly Pro Ile Val Leu Asn Pro Trp Asp Gln Val 115 120 125 Lys Arg
Asn Ala Gly Pro Phe Thr Pro Thr Val Asn Arg Glu Gln Leu 130 135 140
Ser Thr Ser Glu Glu Asn Ser Lys Lys Thr Ile Asp Met Glu Ser Thr 145
150 155 160 Glu Val Phe Thr Lys Lys Thr Lys Leu Thr Glu Glu Glu Lys
Asn Arg 165 170 175 Leu Asn Phe Leu Lys Ile Ile Ser Gln Tyr Tyr Gln
Lys Phe Ala Trp 180 185 190 Pro Gln Tyr Leu Lys Thr Val Asp Gln His
Gln Lys Ala Met Lys Pro 195 200 205 Trp Thr Gln Pro Lys Thr Asn Ala
Ile Pro Tyr Val Arg Tyr Leu 210 215 220 13 179 PRT Oryctolagus
cuniculus PROPEP (1)..(179) Amino acid sequence of rabbit alpha-S2
casein form b precursor from -15 to 167 13 Met Lys Phe Phe Ile Phe
Thr Cys Leu Leu Ala Val Ala Leu Ala Lys 1 5 10 15 Pro Lys Ile Glu
Gln Ser Ser Ser Glu Glu Thr Ile Ala Val Ser Gln 20 25 30 Glu Val
Ser Pro Asn Leu Glu Asn Ile Cys Ser Thr Ala Cys Glu Glu 35 40 45
Pro Ile Lys Asn Ile Asn Glu Val Glu Tyr Val Glu Val Pro Thr Glu 50
55 60 Ile Lys Asp Gln Glu Phe Tyr Gln Lys Val Asn Leu Leu Gln Tyr
Leu 65 70 75 80 Gln Ala Leu Tyr Gln Tyr Pro Thr Val Met Asp Pro Trp
Thr Arg Ala 85 90 95 Glu Thr Lys Ala Ile Pro Phe Ile Arg Thr Met
Gln Tyr Lys Gln Glu 100 105 110 Lys Asp Ala Thr Lys His Thr Ser Gln
Lys Thr Glu Leu Thr Glu Glu 115 120 125 Glu Lys Ala Phe Leu Lys Tyr
Leu Asp Glu Met Lys Gln Tyr Tyr Gln 130 135 140 Lys Phe Val Phe Pro
Gln Tyr Leu Lys Asn Ala His His Phe Gln Lys 145 150 155 160 Thr Met
Asn Pro Trp Asn His Val Lys Thr Ile Ile Tyr Gln Ser Val 165 170 175
Pro Thr Leu 14 223 PRT Ovis sp. PROPEP (1)..(223) Amino acid
sequence of sheep alpha-S2 casein precursor. 14 Met Lys Phe Phe Ile
Phe Thr Cys Leu Leu Ala Val Ala Leu Ala Lys 1 5 10 15 His Lys Met
Glu His Val Ser Ser Ser Glu Glu Pro Ile Asn Ile Ser 20 25 30 Gln
Glu Ile Tyr Lys Gln Glu Lys Asn Met Ala Ile His Pro Arg Lys 35 40
45 Glu Lys Leu Cys Thr Thr Ser Cys Glu Glu Val Val Arg Asn Ala Asp
50 55 60 Glu Glu Glu Tyr Ser Ile Arg Ser Ser Ser Glu Glu Ser Ala
Glu Val 65 70 75 80 Ala Pro Glu Glu Val Lys Ile Thr Val Asp Asp Lys
His Tyr Gln Lys 85 90 95 Ala Leu Asn Glu Ile Asn Gln Phe Tyr Gln
Lys Phe Pro Gln Tyr Leu 100 105 110 Gln Tyr Leu Tyr Gln Gly Pro Ile
Val Leu Asn Pro Trp Asp Gln Val 115 120 125 Lys Arg Asn Ala Gly Pro
Phe Thr Pro Thr Val Asn Arg Glu Gln Leu 130 135 140 Ser Thr Ser Glu
Glu Asn Ser Lys Lys Thr Ile Asp Met Glu Ser Thr 145 150 155 160 Glu
Val Phe Thr Lys Lys Thr Lys Leu Thr Glu Glu Glu Lys Asn Arg 165 170
175 Leu Asn Phe Leu Lys Lys Ile Ser Gln Tyr Tyr Gln Lys Phe Ala Trp
180 185 190 Pro Gln Tyr Leu Lys Thr Val Asp Gln His Gln Lys Ala Met
Lys Pro 195 200 205 Trp Thr Gln Pro Lys Thr Asn Ala Ile Pro Tyr Val
Arg Tyr Leu 210 215 220 15 235 PRT Sus sp. PROPEP (1)..(235) Amino
acid sequence of pig alpha-S2 casein precursor. 15 Met Lys Phe Phe
Ile Phe Thr Cys Leu Leu Ala Val Ala Phe Ala Lys 1 5 10 15 His Glu
Met Glu His Val Ser Ser Ser Glu Glu Ser Ile Asn Ile Ser 20 25 30
Gln Glu Lys Tyr Lys Gln Glu Lys Asn Val Ile Asn His Pro Ser Lys 35
40 45 Glu Asp Ile Cys Ala Thr Ser Cys Glu Glu Ala Val Arg Asn Ile
Lys 50 55 60 Glu Val Gly Tyr Ala Ser Ser Ser Ser Ser Glu Glu Ser
Val Asp Ile 65 70 75 80 Pro Ala Glu Asn Val Lys Val Thr Val Glu Asp
Lys His Tyr Leu Lys 85 90 95 Gln Leu Glu Lys Ile Ser Gln Phe Tyr
Gln Lys Phe Pro Gln Tyr Leu 100 105 110 Gln Ala Leu Tyr Gln Ala Gln
Ile Val Met Asn Pro Trp Asp Gln Thr 115 120 125 Lys Thr Ser Ala Tyr
Pro Phe Ile Pro Thr Val Ile Gln Ser Gly Glu 130 135 140 Glu Leu Ser
Thr Ser Glu Glu Pro Val Ser Ser Ser Gln Glu Glu Asn 145 150 155 160
Thr Lys Thr Val Asp Met Glu Ser Met Glu Glu Phe Thr Lys Lys Thr 165
170 175 Glu Leu Thr Glu Glu Glu Lys Asn Arg Ile Lys Phe Leu Asn Lys
Ile 180 185 190 Lys Gln Tyr Tyr Gln Lys Phe Thr Trp Pro Gln Tyr Ile
Lys Thr Val 195 200 205 His Gln Lys Gln Lys Ala Met Lys Pro Trp Asn
His Ile Lys Thr Asn 210 215 220 Ser Tyr Gln Ile Ile Pro Asn Leu Arg
Tyr Phe 225 230 235 16 5 PRT Bos taurus PEPTIDE (1)..(5) Amino acid
of peptide derived from bovine alpha-S2 casein precursor 16 Lys Val
Ile Pro Tyr 1 5 17 6 PRT Bos taurus PEPTIDE (1)..(6) Amino acid of
peptide derived from bovine alpha-S2 casein precursor 17 Thr Lys
Val Ile Pro Tyr 1 5 18 7 PRT Bos taurus PEPTIDE (1)..(7) Amino acid
of peptide derived from bovine alpha-S2 casein precursor 18 Lys Thr
Lys Val Ile Pro Tyr 1 5 19 8 PRT Bos taurus PEPTIDE (1)..(8) Amino
acid of peptide derived from bovine alpha-S2 casein precursor 19
Pro Lys Thr Lys Val Ile Pro Tyr 1 5 20 9 PRT Bos taurus PEPTIDE
(1)..(9) Amino acid of peptide derived from bovine alpha-S2 casein
precursor 20 Gln Pro Lys Thr Lys Val Ile Pro Tyr 1 5 21 15 PRT Bos
taurus PEPTIDE (1)..(15) Amino acid of peptide derived from bovine
alpha-S2 casein precursor 21 Ala Met Lys Pro Trp Ile Gln Pro Lys
Thr Lys Val Ile Pro Tyr 1 5 10 15 22 22 PRT Bos taurus PEPTIDE
(1)..(22) Amino acid of peptide derived from bovine alpha-S2 casein
precursor 22 Thr Val Tyr Gln His Gln Lys Ala Met Lys Pro Trp Ile
Gln Pro Lys 1 5 10 15 Thr Lys Val Ile Pro Tyr 20 23 27 PRT Bos
taurus PEPTIDE (1)..(27) Amino acid sequence of bovine alpha-S2
casein precursor 23 Pro Gln Tyr Leu Lys Thr Val Tyr Gln His Gln Lys
Ala Met Lys Pro 1 5 10 15 Trp Ile Gln Pro Lys Thr Lys Val Ile Pro
Tyr 20 25
* * * * *